Takegoshi Yusuke, Nagaoka Kentaro, Kido Toshiki, Kawasuji Hitoshi, Murai Yushi, Kaneda Makito, Kimoto Kou, Tani Hideki, Niimi Hideki, Morinaga Yoshitomo, Yamamoto Yoshihiro
Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences, Toyama University, Toyama, Japan.
Clinical and Research Center for Infectious Diseases, Toyama University Hospital, Toyama, Japan.
Ann Transl Med. 2024 Oct 20;12(5):87. doi: 10.21037/atm-24-36. Epub 2024 Sep 19.
Sore throat is a prevalent symptom of coronavirus disease 2019 (COVID-19), particularly when caused by the Omicron variants. However, the association between sore throat and immune responses to different severe acute respiratory syndrome coronavirus 2 variants remains unclear. This study aimed to elucidate the characteristics of immune responses associated with sore throat in patients with COVID-19 before and after the emergence of Omicron.
In this prospective observational study, we enrolled patients with COVID-19 hospitalized between December 2020 and April 2022, which covered the pre-Omicron and Omicron (BA.1 variant) endemic periods. Sore throat was assessed using a daily questionnaire, including an analog scale for sore throat grade (0 to 3) from admission until discharge. Serum levels of immune indicators were assessed using enzyme-linked immunosorbent assay.
A total of 47 patients infected with Omicron and 136 patients infected with preceding variants were included in the analyses. The frequency of sore throat was significantly higher in participants infected with Omicron than that in those infected with preceding variants (66% 42%, P<0.005). Sore throat was associated with nasopharyngeal viral load, interleukin-6 (IL-6)/interferon-α (IFN-α) levels in participants infected with preceding variants, whereas, it was associated with age, the body mass index, and interferon-λ1 (IFN-λ1) in participants infected with Omicron.
Infection with the Omicron variant is characterized by increased sore throat frequency and altered associations between sore throat and several immune indicators, including IFN-α, IL-6, and IFN-λ1.
喉咙痛是2019冠状病毒病(COVID-19)的常见症状,尤其是由奥密克戎变异株引起时。然而,喉咙痛与针对不同严重急性呼吸综合征冠状病毒2变异株的免疫反应之间的关联仍不清楚。本研究旨在阐明奥密克戎出现前后COVID-19患者中与喉咙痛相关的免疫反应特征。
在这项前瞻性观察研究中,我们纳入了2020年12月至2022年4月期间住院的COVID-19患者,涵盖了奥密克戎出现前和奥密克戎(BA.1变异株)流行期。使用每日问卷评估喉咙痛情况,包括从入院到出院的喉咙痛分级模拟量表(0至3级)。使用酶联免疫吸附测定法评估免疫指标的血清水平。
分析共纳入47例感染奥密克戎的患者和136例感染先前变异株的患者。感染奥密克戎的参与者喉咙痛的发生率显著高于感染先前变异株的参与者(66%对42%,P<0.005)。在感染先前变异株的参与者中,喉咙痛与鼻咽病毒载量、白细胞介素-6(IL-6)/干扰素-α(IFN-α)水平相关,而在感染奥密克戎的参与者中,喉咙痛与年龄、体重指数和干扰素-λ1(IFN-λ1)相关。
感染奥密克戎变异株的特征是喉咙痛频率增加,以及喉咙痛与包括IFN-α、IL-6和IFN-λ1在内的几种免疫指标之间的关联改变。